Earnings Call Transcript Analysis Report #
IOL Chemicals and Pharmaceuticals Limited - FY25 Financial Performance #
Revenue #
- Q4 FY25: Revenue from operations grew to INR 528 crores, a 4.7% year-on-year (YoY) increase from INR 504 crores in Q4 FY24.
- FY25: Full-year revenue stood at INR 2,079 crores.
EBITDA #
- Q4 FY25: Increased by 17% YoY to approximately INR 67 crores from INR 58 crores in Q4 FY24.
- Q4 FY25 EBITDA Margin: 12.7%, an improvement of 141 basis points YoY.
- FY25: EBITDA stood at INR 225 crores.
- FY25 EBITDA Margin: Approximately 11%.
Profit After Tax (PAT) #
- Q4 FY25: Grew by 12% YoY to INR 31.6 crores from INR 28 crores in Q4 FY24.
- Q4 FY25 PAT Margin: 5.9%, an increase of 43 basis points YoY.
- FY25: PAT stood at INR 101 crores.
- FY25 PAT Margin: 4.8%.
- Note: PAT was impacted by higher depreciation charges from recent capital investments.
Cash PAT #
- Q4 FY25: Stood at INR 56.4 crores, an increase of about 15% from INR 49.2 crores in Q4 FY24.
- FY25: Cash PAT was INR 185 crores.
Debt #
- Net debt to equity ratio stood at 0.09 at the end of FY25 due to working capital borrowings.